+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations